In summary, GAS5 inhibited NSCLC cisplatin-resistance, metastasis and EMT progression by impairing the endogenous effects of miR-217, thereby promoting LHPP mRNA and protein expression (Figure 9). The gene discussed is LHPP; the disease is non-small cell lung carcinoma.